Expand APLS Menu
APLS MENU

APLS Latest Press Releases

-- April 4, 2024 --

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- April 1, 2024 --

Apellis Pharmaceuticals to Host a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference Globe Newswire 7:00 AM

-- March 19, 2024 --

Investigation Alert: Cummins, Apellis Pharmaceuticals, Inspire Medical, and Applied Digital - Johnson Fistel, LLP Encourages Long-Term Investors to Submit Their Information Below Globe Newswire 3:00 PM

-- March 11, 2024 --

Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor Globe Newswire 7:00 AM

-- March 6, 2024 --

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- March 5, 2024 --

Investigation Alert Driven Brands Holdings, Apellis Pharmaceuticals, Inspire Medical, and Applied Digital: Johnson Fistel, LLP Encourages Long-Term Investors to Submit Their Information Below Globe Newswire 2:07 PM

-- February 27, 2024 --

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results Globe Newswire 7:05 AM

-- February 26, 2024 --

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences Globe Newswire 7:00 AM

-- February 20, 2024 --

Apellis Pharmaceuticals to Host Conference Call on February 27, 2024, to Discuss Fourth Quarter and Full Year 2023 Financial Results Globe Newswire 7:00 AM

-- February 6, 2024 --

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- January 26, 2024 --

Apellis Announces Negative CHMP Opinion for Pegcetacoplan for GA in the European Union and Plans to Seek Re-Examination of Application Globe Newswire 7:06 AM

-- January 16, 2024 --

Investigation Alert Apellis Pharmaceuticals, KeyCorp, ACI Worldwide, and Applied Digital: Johnson Fistel, LLP Encourages Long-Term Investors to Submit Their Information Below Globe Newswire 1:47 PM

-- January 8, 2024 --

Apellis Announces Preliminary Fourth Quarter and Full Year 2023 U.S. Net Product Revenues Globe Newswire 9:00 AM

-- January 5, 2024 --

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- January 2, 2024 --

Apellis Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference Globe Newswire 7:00 AM

-- December 28, 2023 --

Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs Healthcare C-Suite Unscripted Conference Globe Newswire 7:00 AM

-- December 14, 2023 --

Investigation Alert Apellis Pharmaceuticals, KeyCorp, ACI Worldwide, and Applied Digital: Johnson Fistel, LLP Encourages Long-Term Investors to Submit Their Information Below Globe Newswire 12:09 PM
Apellis Provides Update on Ongoing Regulatory Review of Pegcetacoplan for GA in the European Union Globe Newswire 7:00 AM

-- December 11, 2023 --

EMPAVELI (pegcetacoplan) Provided Long-Term Control of PNH in New Data Presented at ASH Annual Meeting Globe Newswire 7:00 AM

-- December 6, 2023 --

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM
Investigation Alert Apellis Pharmaceuticals, KeyCorp, ACI Worldwide, and Applied Digital: Johnson Fistel, LLP Encourages Long-Term Investors to Submit Their Information Below Globe Newswire 12:49 PM

-- November 21, 2023 --

Apellis Pharmaceuticals to Host a Fireside Chat at the 6th Annual Evercore ISI HealthCONx Conference Globe Newswire 7:00 AM